Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQ-A3334 “Toll-like Receptor 7 (TLR7) Agonist” and TQA3605 “Core Protein Modification Modulator” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), a subsidiary of the Group, have all been included in the breakthrough therapeutic drug program by the Drug Evaluation Center (CDE) of the China National Drug Administration. The two innovative drugs address the two major unmet needs in the treatment of chronic hepatitis B (chronic hepatitis B): functional cure and hypoviremia (LLV).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.